Synaptogenix Provides Corporate Update And Outlines Potential Business Opportunities; Remains Well-Funded With ~$37.5M In Cash As Of Year-End 2022 And A Relatively Low Cash Burn Rate
Announces encouraging secondary endpoint results from NIH-sponsored Phase 2 clinical trial of Bryostatin-1 in advanced Alzheimer's disease patients
Maintains strong financial position with approximately $37.5